ULCERATIVE COLITIS

• Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-U … Recruiting
  2023-506452-25-00 4 2025-03-27
• This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (level and body resistance to … Recruiting
  2023-509775-16-00 4 2024-10-03
• A trial to evaluate the efficacy and safety of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) in patients with mild to moderate … Recruiting
  2024-510807-13-00 10 2024-09-12
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16
• A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with u … Recruiting
  2023-507547-11-00 1 2024-02-09
• Effect of Tofacitinib on coagulation and platelet function, and its role in thromboembolic events Recruiting
  2024-518434-83-01 6 2022-06-01
• An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with … Recruiting
  2023-507256-76-00 6 2020-01-14
• Stopping anti-TNF treatment in Crohn's and Colitis patients in remission Recruiting
  2024-513299-17-00 6 2017-05-05
• An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study c … Recruitment ended
  2025-520617-31-00 2 2025-09-12
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Recruitment ended
  2024-518998-33-00 5 2025-07-23
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Recruitment ended
  2022-502238-22-00 5 2024-05-14
• ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Recruitment ended
  2024-515156-21-00 5 2020-01-09
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Recruitment ended
  2023-506994-36-00 5 2018-10-11
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Recruitment ended
  2023-507657-15-00 5 2018-09-13
• Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Recruitment ended
  2023-505699-31-00 5 2017-01-02
• Testing Insulin Enemas for Ulcerative Colitis: A First-Stage Clinical Trial Ended
  2023-510335-11-00 3 2025-02-04
• Study to evaluate food effect on the pharmacokinetics of mesalazine oral formulation in healthy volunteers. Ended
  2024-514748-10-00 3 2024-11-28
• PARADOX study Ended
  2024-515278-28-00 6 2024-11-15
• A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis Ended
  2023-510324-77-00 1 2024-10-20
• A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB … Ended
  2023-507376-50-00 1 2024-09-27
• A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy A … Ended
  2023-507354-32-00 1 2024-09-09
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30
• Unravelling intestinal fibrosis in ulcerative colitis: INTERACT study Ended
  2023-507907-73-00 11 2024-04-03
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06

Showing 25–48 of 61 trials